PubMed Health⌕ Search

Biomedical subjects

E Marsaudon

Publications and source records attributed to E Marsaudon.

11 recordsLinked to original sources
PubMed1999

[Spinal cord compression due to tophaceous vertebral gout: a case report and literature review].

INTRODUCTION: Acute gout arthritis and tophaceous gout of the spine is rare. EXEGESIS: We report the case of a 54-year-old man with chronic low back pain. Physical examination and myelography showing neurological compression on L4 laminectomy evidenced tophaceous gout. CONCLUSION: Gout arthritis should always be suspected and investigated in patients with either chronic low back pain or non-specific spinal cord compression.

Arthritis, Gouty↗
PubMed1997

[Infectious complications after peridural obstetric anesthesia].

Infective complications after epidural anesthesia for delivery are uncommon. We reviewed 21 cases of epidural abscesses, 7 cases of meningitis and one spondylitis reported in the literature. These infections usually occurred in debilitated patients either by direct contamination at puncture or indirectly from a neighboring infection or from the blood stream. Prognosis depends on early diagnosis. The first manifestations are spinal stiffness or local pain. Signs of neurological deficiency come later at a stage when complete recovery is compromised. This emphasizes the importance of the clinical examination before delivery in search for skin or deep infections.

Abscess↗
PubMed1997

[Diffuse interstitial lung disease without pleural involvement and high-dose bromocriptine].

Bromocriptine, used in the treatment of acromegaly, hyperprolactinemia and Parkinson's disease, may be responsible in this last case, for pleuro-pulmonary complications in higher doses. Since 1981 about thirty cases were described. It was mostly pleural effusions, pleural thickening and parenchymal lung fibrosis. The prevalence of pleuro-pulmonary diseases is between 2 to 5% after 5 years with bromocriptine that varied in dosage from 20 to 90 mg daily. The patients developed symptoms from nine months to four years. We report a case of a patient treated for one year for Parkinson's disease with daily dose of 105 mg of bromocriptine in whom bilateral pulmonary infiltrate was discovered with a deterioration in the general physical state and dyspnea. There was a favorable clinical and chest roentgenogram outcome following the cessation of treatment, in six months. The hypotheses to explain the pathogenesis of these disorders were always discussed: a vascular theory, an immunological theory or a toxic fibrogenesis induced by the molecule acting on dopaminergic receptors and serotonergic synapses. Now, in our knowledge, these complications justify a clinical and chest roentgenogram follow up for any patients treated with bromocriptine.

Aged↗